Pfizer

PFE
27.4000.51% ( -0.140 )
Closed: Nov 20, 16:00:00 (EDT)

News

  • Pfizer (PFE) Stock Looks Stretched Even With New Pipeline Deals

    Simplywall·
    - Pfizer is trading around US$ 27.40 after a 33.5 % share price decline over the past 5 years. - The company trades at a P / E ratio of 38.7 x, exceeding the pharmaceuticals sector average of 15.2 x while remaining below peer levels. - Analyst views are divided, with consensus pointing to potential undervaluation based on US$ 9.7 b in net savings through 2029, while bearish views suggest limited room for error.
  • Weekly Recap | Pfizer -5.16%, outperforming the S&P 500

    Weekly Review·
    - Pfizer accumulated a 5.16 % decline to close at 27.4 dollars this week, outperforming the S & P 500 index by approximately 3.45 percentage points amid a broader market pullback. - The company announced a 2.6 billion dollar licensing agreement with Starna Therapeutics focusing on CAR-T therapies for autoimmune diseases and remained a subject of industry-wide discussions regarding artificial intelligence integration. - Institutional coverage showed a consensus rating of neutral with an average target price of 30.22 dollars, while upcoming catalysts include the execution of the new licensing agreement and dense macroeconomic data releases.
  • Missed Pfizer's Rally? Here Is What Holders Saw

    Simplywall·
    - Pfizer delivered a 20.3% total return over the past year, with shares trading at US$28.06 amidst a debate between bullish oncology expansion and bearish patent expiration views. - Bullish investors targeted a Fair Value of US$28.77 driven by cancer drugs and vaccines, while bears estimated a Fair Value of US$23.58 due to pricing pressure and revenue declines. - Recent financial data showed Q3 2026 revenue slipping to US$16,583m and net income easing to US$3,242m, indicating current prices rely heavily on flawless execution of cost savings and pipeline delivery.
  • Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies

    Pharmaceutical Technology·
    - Pfizer has signed a $2.6bn licensing agreement with China’s Starna Therapeutics to acquire ex-China rights to 3 pre-IND in vivo CAR-T programmes for autoimmune diseases. - The deal includes $330m upfront, up to $2.3bn in milestones, and royalties, alongside rights to use Starna’s technology in inflammation, immunology, and oncology. - This acquisition aligns with a broader industry trend where major drugmakers increasingly invest in in vivo CAR-T therapies to overcome manufacturing and scalability hurdles.
  • Pfizer Inc. Stock Outperforms Competitors Despite Losses On The Day

    MarketWatch Automated·
    - Pfizer Inc. shares fell 1.44 % to $28.06 on Wednesday, marking the third consecutive day of losses amid a broader market downturn. - Despite the decline, the stock outperformed several major competitors such as Johnson & Johnson and Eli Lilly during the session. - Trading volume reached 37.2 million, surpassing the 50-day average volume of 33.5 million.
  • Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments

    PUBT·
    - Pfizer entered an exclusive licensing agreement with Starna Therapeutics for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. - Starna will receive $330 million upfront, along with up to $2.3 billion in potential milestones and royalties on net sales. - The agreement grants Pfizer exclusive rights for development, manufacturing, and commercialization outside Greater China.
  • Leerink Partners Keeps Their Hold Rating on Pfizer (PFE)

    Tip Ranks·
    - Leerink Partners maintained a Hold rating on Pfizer with shares closing at $ 28.86 yesterday. - The company also received a Hold rating from DZ BANK AG on November 5. - Barclays maintained a Sell rating on Pfizer in recent reports.
  • Datapharm expands SRD Search into France

    PharmaTimes·
    - Datapharm has launched its SRD Search functionality on VIDAL in France, marking the third market expansion following the UK and Germany. - Pfizer became the first pharmaceutical company to publish 373 French-language Scientific Response Documents covering 9 brands since the service went live in August 2026. - The expansion aims to provide French healthcare professionals with 24/7 access to trusted medicine information while delivering valuable search analytics to manufacturers.
  • Is Pfizer (PFE) Undervalued On Its $1.5b Berobenatide Funding Deal?

    Simplywall·
    - Pfizer secured up to US$ 1.5b in external funding from Blackstone Life Sciences for its investigational obesity drug berobenatide while retaining full program ownership. - The company trades at US$ 28.89 against an analyst consensus fair value of US$ 29.72, leading market narratives to view it as 3% undervalued. - Growth in non-COVID therapies and extensive cost savings support operating margins, though risks remain from potential drug pricing reforms and pipeline execution.
  • Weekly Recap | Pfizer -1.7%, Blackstone backs GLP-1 push

    Weekly Review·
    - Pfizer stock fell 1.7% to close at 28.89 USD this week, underperforming the S&P 500 by 4.21 percentage points. - Key corporate developments involved a 1.5 billion USD financing agreement with Blackstone Life Sciences for GLP-1 clinical trials and adjustments to its product portfolio. - Wall Street maintained a neutral consensus rating with a target price of 30.22115 USD, reflecting divided institutional outlooks on future earnings.
  • Pfizer (PFE) Stock Looks Above Fair Value As Shares Rebound

    Simplywall·
    - Pfizer trades at a P / E ratio of approximately 40.8x, which significantly exceeds the Pharmaceuticals sector average of about 14.0x. - Bullish perspectives attribute potential value to cost savings, new therapy launches, and an obesity partnership with Blackstone Life Sciences. - Bearish viewpoints emphasize execution risks and potential revenue declines from patent cliffs between 2026 and 2030.
  • Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market

    benzinga_article·
    - Pfizer Inc. is permanently discontinuing the sale of its menopause hormone therapy Premarin in Canada following an internal review. - The withdrawal includes Premarin vaginal cream and three oral tablet strengths, potentially increasing pressure on Canada's constrained menopause drug supply alongside ongoing estradiol patch shortages. - Existing inventories of oral tablets are expected to last until mid-2027, while hospital treatments utilizing Premarin Intravenous remain unaffected.
  • 2 Bargain Stocks to Buy With $1,000 in November

    Motley Fool·
    - Pfizer and Alphabet are highlighted as two bargain stocks to buy for long-term investors entering the new year. - Pfizer trades at 10 times next year's expected earnings with a 6% dividend yield as it rebuilds its R&D pipeline through acquisitions to offset patent expirations. - Alphabet trades at less than 20 times expected earnings following a recent earnings miss and rising AI capital expenditures, though analysts maintain a strong buy consensus.
  • Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund

    Pharmaceutical Technology·
    - Pfizer secured $ 1.5bn in funding from Blackstone Life Sciences to support the clinical development of its monthly GLP- 1RA obesity drug berobenatide through 2028. - Blackstone will receive milestone-based payments tied to US market entry and sales figures without gaining ownership rights to the asset. - The financial agreement allows Pfizer to advance its extensive Phase III obesity trials while reducing near-term financial burdens in a market dominated by Eli Lilly and Novo Nordisk.